Stryker Sells U.S. Spinal Implants Business, CFO To Retire

Stryker Stock Falls on Deal to Sell Its U.S. Spinal Implants Business
Stryker Corporation SYK recently announced a definitive agreement to sell its U.S. spinal implants business to Viscogliosi Brothers, LLC, a family-owned investment firm specializing in the neuro-musculoskeletal space,
Stryker to spin off spinal implant business, as Viscogliosi Brothers-owned VB Spine
Stryker is selling off its spine implant business—starting with a plan to spin off its U.S. operations before moving on to divest its international enterprises in the months to come. | Stryker is selling off its spine implant business—starting with a plan to spin off its U.
Stryker will sell spine implant business; CFO set to retire
The buyer, Viscogliosi Brothers, will call the company VB Spine. Stryker also reported operating results and offered its outlook for 2025.
Stryker to sell spinal implants business
Stryker reported goodwill and other impairments of $818 million related to the spine business in the fourth quarter. Stryker’s spinal implants business brought in $707 million in sales in 2024, and Lobo clarified that the “entire $700 million is expected to be divested to [VB Spine].”
Stryker to Sell Spinal Implants Business to Viscogliosi Brothers
Stryker has agreed to sell its U.S. spinal implants business to Viscogliosi Brothers to create a newly formed company called VB Spine. The medical technology company said Tuesday the New York City-based Viscogliosi Brothers specializes in neuro-musculoskeletal treatments.
Stryker announces definitive agreement for the sale of its U.S. spinal implants business and plans to sell related international business
Stryker (NYSE:SYK), a global leader in medical technologies, announced today a definitive agreement to sell its U.S. spinal implants business to Viscogliosi Brothers, LLC, a family-owned investment firm specializing in the neuro-musculoskeletal space,
Stryker's SWOT analysis: medical tech giant's stock poised for growth
Stryker Corporation (NYSE:SYK), a leading player in the medical technology industry with a substantial market capitalization of $149 billion, has been making waves with its strong financial ...
Stryker: A Cool Name For An Awesome Company, But Is It A Buy Ahead Of Earnings?
Stryker Corporation's innovation and market leadership justify a premium. See why SYK stock is a solid hold with long-term ...
Stryker reports 2024 operating results and 2025 outlook
Stryker (NYSE:SYK) reported operating results for the fourth quarter and full year of 2024: Fourth Quarter Results Full Year Results “We delivered another year of double-digit organic sales growth ...
A Glimpse Into The Expert Outlook On Stryker Through 14 Analysts
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by ...
Stryker to Sell its U.S. Spinal Implants Business
“We believe that the spinal implants business, with its comprehensive portfolio and strong sales channel, will thrive as an ...
Stryker’s Strategic Moves and Strong Performance Drive Buy Rating
In a report released today, Michael Matson from Needham reiterated a Buy rating on Stryker (SYK – Research Report), with a price target of ...
Stryker forecasts 2025 profit above estimates on robust demand for surgical devices
Stryker beat Wall Street estimates for fourth-quarter profit and forecast 2025 earnings largely above expectations on Tuesday, fueled by strong demand for its medical and surgical devices. Medical and ...
Q4 2024 Stryker Corp Earnings Call
Danielle Antalffy; Analyst; UBS Equities Michael Polark; Analyst; Wolfe Research ...